相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Overcoming the Challenges of Pyrazinamide Susceptibility Testing in Clinical Mycobacterium tuberculosis Isolates
Simone Mok et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
HOW COVID HURT THE FIGHT AGAINST OTHER DEADLY DISEASES
Leslie Roberts
NATURE (2021)
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis
S. E. Dorman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
High prevalence of phenotypic pyrazinamide resistance and its association with pncA gene mutations in Mycobacterium tuberculosis isolates from Uganda
Resty Naluyange et al.
PLOS ONE (2020)
How To Optimally Combine Genotypic and Phenotypic Drug Susceptibility Testing Methods for Pyrazinamide
Claudio U. Koser et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Pyrazinoic Acid Inhibits the Bifunctional Enzyme (Rv2783) in Mycobacterium tuberculosis by Competing with tmRNA
Lei He et al.
PATHOGENS (2019)
Intracellular Mycobacterium tuberculosis Exploits Multiple Host Nitrogen Sources during Growth in Human Macrophages
Khushboo Borah et al.
CELL REPORTS (2019)
Validating a 14-Drug Microtiter Plate Containing Bedaquiline and Delamanid for Large-Scale Research Susceptibility Testing of Mycobacterium tuberculosis
Paola M. V. Rancoita et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
The Continued Value of Disk Diffusion for Assessing Antimicrobial Susceptibility in Clinical Laboratories: Report from the Clinical and Laboratory Standards Institute Methods Development and Standardization Working Group
Romney M. Humphries et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2018)
Mycobacterium tuberculosis Strains H37ra and H37rv have Equivalent Minimum Inhibitory Concentrations to Most Antituberculosis Drugs
M. Tobias Heinrichs et al.
INTERNATIONAL JOURNAL OF MYCOBACTERIOLOGY (2018)
Genotyping and Prevalence of Pyrazinamide- and Moxifloxacin-Resistant Tuberculosis in China, 2000 to 2010
Yu Pang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
In Vivo-Selected Pyrazinoic Acid-Resistant Mycobacterium tuberculosis Strains Harbor Missense Mutations in the Aspartate Decarboxylase PanD and the Unfoldase CIpC1
Pooja Gopal et al.
ACS INFECTIOUS DISEASES (2017)
Pyrazinoic Acid Inhibits Mycobacterial Coenzyme A Biosynthesis by Binding to Aspartate Decarboxylase PanD
Pooja Gopal et al.
ACS INFECTIOUS DISEASES (2017)
Anti-tubercular Activity of Pyrazinamide is Independent of trans-Translation and RpsA
Nicholas A. Dillon et al.
SCIENTIFIC REPORTS (2017)
Pyrazinoic Acid Inhibits a Bifunctional Enzyme in Mycobacterium tuberculosis
Moses Njire et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Pyrazinamide Is Active against Mycobacterium tuberculosis Cultures at Neutral pH and Low Temperature
Alice L. den Hertog et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Sensititre® MYCOTB MIC plate for drug susceptibility testing of Mycobacterium tuberculosis complex isolates
X. Yu et al.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2016)
A Multilaboratory, Multicountry Study To Determine MIC Quality Control Ranges for Phenotypic Drug Susceptibility Testing of Selected First-Line Antituberculosis Drugs, Second-Line Injectables, Fluoroquinolones, Clofazimine, and Linezolid
Kone Kaniga et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2016)
Pyrazinamide Resistance Is Caused by Two Distinct Mechanisms: Prevention of Coenzyme A Depletion and Loss of Virulence Factor Synthesis
Pooja Gopal et al.
ACS INFECTIOUS DISEASES (2016)
Uncoupling Environmental pH and Intrabacterial Acidification from Pyrazinamide Susceptibility in Mycobacterium tuberculosis
Nicholas D. Peterson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Mycobacterium tuberculosis pncA Polymorphisms That Do Not Confer Pyrazinamide Resistance at a Breakpoint Concentration of 100 Micrograms per Milliliter in MGIT
Michael G. Whitfield et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2015)
Structural basis for targeting the ribosomal protein S1 of Mycobacterium tuberculosis by pyrazinamide
Juanjuan Yang et al.
MOLECULAR MICROBIOLOGY (2015)
A Global Perspective on Pyrazinamide Resistance: Systematic Review and Meta-Analysis
Michael G. Whitfield et al.
PLOS ONE (2015)
Pantothenate and Pantetheine Antagonize the Antitubercular Activity of Pyrazinamide
Nicholas A. Dillon et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Aspartate decarboxylase (PanD) as a new target of pyrazinamide in Mycobacterium tuberculosis
Wanliang Shi et al.
EMERGING MICROBES & INFECTIONS (2014)
Mechanisms of Pyrazinamide Action and Resistance
Ying Zhang et al.
MICROBIOLOGY SPECTRUM (2014)
Evaluation of the Sensititre MycoTB Plate for Susceptibility Testing of the Mycobacterium tuberculosis Complex against First- and Second-Line Agents
Leslie Hall et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2012)
Effects of low incubation temperatures on the bactericidal activity of anti-tuberculosis drugs
David Coleman et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
Pyrazinamide Inhibits Trans-Translation in Mycobacterium tuberculosis
Wanliang Shi et al.
SCIENCE (2011)
Antimicrobial Susceptibility Testing of Mycobacterium Tuberculosis Complex for First and Second Line Drugs by Broth Dilution in a Microtiter Plate Format
Leslie Hall et al.
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS (2011)
Biology of trans-Translation
Kenneth C. Keiler
ANNUAL REVIEW OF MICROBIOLOGY (2008)
Enhancement of the antituberculosis activity of weak acids by inhibitors of energy metabolism but not by anaerobiosis suggests that weak acids act differently from the front-line tuberculosis drug pyrazinamide
Peihua Gu et al.
JOURNAL OF MEDICAL MICROBIOLOGY (2008)
Mycobacterium tuberculosis and the environment within the phagosome
Kyle Rohde et al.
IMMUNOLOGICAL REVIEWS (2007)
Nutrient-starved incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis
Qiang Huang et al.
CHEMOTHERAPY (2007)
Effects of weak acids, UV and proton motive force inhibitors on pyrazinamide activity against Mycobacterium tuberculosis in vitro
Mary Margaret Wade et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2006)
Anaerobic incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis
MM Wade et al.
JOURNAL OF MEDICAL MICROBIOLOGY (2004)
Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid
Y Zhang et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2003)
Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I
HI Boshoff et al.
JOURNAL OF BACTERIOLOGY (2002)
Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide
Y Zhang et al.
JOURNAL OF MEDICAL MICROBIOLOGY (2002)
Comparison of phenotypic and genotypic methods for pyrazinamide susceptibility testing with Mycobacterium tuberculosis
AP Davies et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2000)
Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis
O Zimhony et al.
NATURE MEDICINE (2000)
分享论文
